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Interindividual variability in the expression and function of drug metabolizing cytochrome P (CYP) 450 
enzymes, determined by a combination of genetic, non-genetic and environmental parameters, is a 
major source of variable drug response. Phenotyping by administration of a selective enzyme 
substrate, followed by the determination of a specific phenotyping metric, is an appropriate 
approach to assess the in vivo activity of CYP450 enzymes, as it takes into account all influencing 
factors. A phenotyping protocol should be as simple and convenient as possible. Typically, 
phenotyping metrics are determined in traditional matrices, such as blood, plasma or urine. Several 
sampling strategies have been proposed as an alternative for these traditional sampling techniques. 
In this review, we provide a comprehensive overview of available methods using dried blood spots, 
hair, oral fluid, exhaled breath and sweat for in vivo CYP450 phenotyping. We discuss the relation 
between phenotyping metrics measured in these samples and those in conventional matrices, along 
with the advantages and limitations of the alternative sampling techniques. Reliable phenotyping 
procedures for several clinically relevant CYP450 enzymes, including CYP1A2, CYP2C19 and CYP2D6, 
are currently available for oral fluid, breath or dried blood spots, while additional studies are needed 
for other CYP450 isoforms, such as CYP3A4. The role of hair analysis for this purpose remains to be 
established. Being non- or minimally invasive, these sampling strategies provide convenient and 
patient-friendly alternatives for classical phenotyping procedures, which may contribute to the 





 Phenotyping by administration of a selective probe drug, followed by determination of 
a specific phenotyping metric, allows to assess the in vivo enzyme activity of CYP450 
enzymes, taking into account genetic, non-genetic and environmental influencing 
factors. 
 In addition to classical sampling techniques, such as blood or urine collection, reliable 
phenotyping procedures for several clinically relevant CYP450 enzymes are currently 
available for oral fluid, breath and dried blood spots. 
 Alternative sampling strategies may aid to implement CYP450 phenotyping in clinical 





Enzymatic biotransformation is one of the main routes of elimination of drugs and other xenobiotics 
from the human body. These enzymatic processes can be divided into two phases: compounds are 
modified by oxidation, reduction or hydrolysis in phase I, while conjugation reactions in phase II 
typically increase the hydrophilic character of substrates by adding endogenous molecules, such as 
glucuronic acid or gluthathion. Phase I metabolism, being the rate-limiting step of enzymatic 
biotransformation, is mainly catalyzed by cytochrome P (CYP) 450 enzymes [1]. CYP450 is a 
superfamily of heme-containing enzymes located primarily in the endoplasmatic reticulum of liver 
cells and enterocytes in the epithelium of the small intestine. On the basis of increasing amino acid 
similarity, this group of enzymes is divided into families and subfamilies, denoted by numbers and 
letters, respectively. Individual enzymes within a subfamily are given an additional number. While 57 
functional human CYP450 genes have been identified, only a limited number of the resulting proteins 
plays a role in the metabolism of drugs. The latter enzymes mainly belong to the CYP1, CYP2 and 
CYP3 families [2].  
Many CYP450 enzymes display a considerable interindividual variability in their expression and 
function, which is determined by a combination of genetic, epigenetic and non-genetic host factors 
(e.g. sex, age, pathophysiological conditions) as well as environmental influences (e.g. diet, tobacco 
smoke, drug intake) [3]. Consequently, each individual has its own CYP450 metabolic profile. As it is 
estimated that the major CYP450 enzymes are involved in 70-80 % of phase I reactions metabolizing 
clinically used drugs [4], variability in enzyme activity may result in variability in bioavailable drug 
levels and, consequently, variable response to drug therapy. When the parent drug is 
pharmacologically active, impaired enzyme function may increase the risk of developing adverse drug 
reactions (ADRs). For example, Phillips et al. found that 59 % of drugs cited in ADR studies are, at 
least partially, metabolized by enzymes with reduced function [5]. Likewise, when metabolization 
results in inactivation of a parent drug, higher than normal enzyme activity may cause standard drug 
therapy to fail. In these cases, increasing the drug dose is needed to obtain the same level of efficacy 
[3,6].  
Therefore, estimating the metabolic status of an individual for a given pathway can be a useful tool 
to explain unexpected drug plasma concentrations, identify causes of ADRs, guide therapy or even 
predict the appropriate drug dose prior to the start of a therapy. Some CYP450 enzymes, in particular 
CYP2D6, CYP2C19 and CYP2C9, are encoded by highly polymorphic genes and distinct subpopulations 
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can be identified based on the genetic signature [4,7,8]. For many drugs metabolized by these 
enzymes, clinical outcome could be correlated with a certain genotype and genotyping a patient has 
proven to be a reliable strategy to assess the metabolic phenotype [3,6,8]. This approach holds the 
advantages that is has to be performed only once for each individual and that intake of test drugs is 
not required. Also for other important CYP450 enzymes, such as CYP1A2 and CYP3A4, a wide 
interindividual variability in enzyme activity has been described. Although multiple polymorphisms of 
the respective genes have been identified, variant alleles giving rise to altered enzyme function are 
very rare and genetic factors alone are unable to fully explain the variation in enzyme function [2,9]. 
These enzymes are highly influenced by environmental factors, such as inhibitor or inducer drugs, 
diet components and tobacco smoke [3]. Therefore, phenotyping by administration of a selective 
substrate is the preferred approach to assess the in vivo activity of these enzymes, as it takes into 
account genetic, non-genetic and environmental influences. In addition, even for those enzymes 
whose function is mainly genetically controlled, individuals that were genotyped as extensive 
metabolizers may display a (transient) poor metabolizer phenotype, due to intake of enzyme-
inhibiting drugs or certain comorbidities influencing enzyme activity, such as HIV, liver disease and 
cancer. This phenomenon, called phenoconversion, has been observed mainly for CYP2D6 and 
CYP2C19 [10]. Also here, phenotyping can be applied in conjunction with genotyping to obtain an 
integrated image of enzyme function.  
In general, phenotyping for a drug metabolizing enzyme is performed by the administration of a 
selective substrate of the enzyme, followed by the determination of a specific phenotyping metric. 
The latter may comprise various pharmacokinetic parameters, such as the systemic clearance of the 
probe drug, single point concentrations or metabolite/parent drug concentration ratios (or parent 
drug/metabolite ratios), typically obtained from plasma or urine samples. Multiple probe drugs and 
phenotyping protocols have been described for different CYP450 enzymes, amongst which several 
have been validated to provide a reliable estimate of the actual enzyme activity. We refer to the 
work of Streetman et al. [11] and Fuhr et al. [12] for an overview of available phenotyping 
procedures. Fuhr et al. also discussed the requirements for appropriate phenotyping procedures. 
Apart from the use of selective substrates and metrics and the need of probe drugs with an 
acceptable safety profile, reliable analytics and low intraindividual variability of the metric, the 
authors stated that phenotyping procedures ideally should be simple and convenient. The use of 
alternative samples strategies instead of traditional blood/plasma or urine sampling may fulfill this 
requirement. The major drawback of venous blood sampling in the context of phenotyping is 
probably the inherent invasiveness, which may specifically pose a problem when repeated sampling 
is needed to construct a full concentration-time profile. The latter is, for example, required in drug-
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drug interaction studies as this approach takes into account the influence of various factors on the 
kinetics of the probe drug, including processes other than enzyme activity. In addition, venipuncture 
requires specialized staff. Concerning urine sampling, the susceptibility to non-specific noise caused 
by urinary flow or pH is a matter of concern. For example, urinary metabolic ratios of the probe drugs 
caffeine and dextromethorphan for phenotyping of CYP1A2 and CYP2D6, respectively, showed high 
intraindividual variability caused by these variables [13,14]. Furthermore, phenotyping protocols 
often require that urine is collected over a period of several hours. Apart from being inconvenient for 
the patient, this impedes efficient transport of samples.  
This review aims at providing an overview of alternative sampling strategies for in vivo CYP450 
phenotyping. More specifically, the use of dried blood spots, hair, oral fluid, exhaled breath and 
sweat for this purpose will be discussed. Special emphasis was placed on how phenotyping metrics 
measured in these alternative samples relate to those in conventional matrices, as we believe that 
this is a key point to evaluate the validity and usefulness of alternative sampling strategies for 
CYP450 phenotyping. A discussion on the actual therapeutic usefulness of phenotyping for individual 
enzymes was out of the scope of this work. A structured literature search was performed using 
PubMed (U.S National Library of Medicine) and ISI Web of Science™ databases. Keywords were 
cytochrome P (CYP) 450, all major CYP450 isoforms, phenotyping, enzyme activity and the above 
mentioned matrices. Only articles in English were selected and references of relevant articles were 
screened. Although similar sampling procedures as discussed here can also be used for phenotyping 
other drug metabolizing enzymes, such as conjugative phase II enzymes, these are not covered by 
this review. 
2 Dried blood spots 
Since Guthrie and Susi proposed to use newborn dried blood spots (DBS) to determine 
phenylketonuria [15], DBS sampling and analysis has been extensively used in newborn screening 
programs. The availability of highly sensitive analytical techniques, mainly liquid chromatography – 
tandem mass spectrometry (LC-MS/MS), resulted in an exponential increase in the interest in DBS for 
applications in other fields, including therapeutic drug monitoring [16,17], toxicology [18,19] and 
toxico- and pharmacokinetic studies in (pre-)clinical phases of drug development [20-22]. In general, 
DBS are prepared by applying a drop of capillary blood, obtained by a finger or heel prick, on a 
dedicated filter paper card. This can either be performed in a volumetric way, by spotting a defined 
volume of blood using a microcapillary, or non-volumetrically, by direct application of a drop of blood 
from the fingertip. Upon application to the filter paper, the resulting spots are dried to the air. This 
sampling technique offers several advantages over traditional blood sampling by venipuncture. DBS 
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sampling by fingerprick is only minimally invasive and it provides a relatively easy and inexpensive 
way of taking a representative sample. Sample collection can be performed by an informed patient 
himself, eliminating the need for a trained phlebotomist and enabling sampling in a non-specialized 
environment (e.g. at home) [23]. Furthermore, as several compounds showed enhanced stability in 
DBS [24-27], samples can be transferred via regular mail and stored at room temperature in the 
laboratory. The reduced risk of infection, due the fact that pathogens are deactivated upon drying 
[28], further contributes to the convenient and cost-effective transport and storage. From an 
analytical point of view, compounds can often be extracted from DBS cards using straightforward 
procedures, making this technique particularly suitable for automated processing [29-31].  
Despite the many advantages, several issues still surround DBS sampling and analysis. As high quality 
data can only be derived from high quality samples, good sampling practices are of key importance, 
especially when non-experienced individuals are involved. Being a microsampling technique, in which 
small volumes of blood are collected and processed, analytical instruments involved in DBS analysis 
should provide sufficient sensitivity. Furthermore, when capillary DBS are analyzed, knowledge of the 
correlation between capillary and venous concentrations of the analyte of interest is needed [32,33]. 
In this light, thorough interpretation of DBS results often requires comparison with DBS and 
plasma/serum results, as reference intervals or cut-off values are commonly based on the latter [34]. 
Apart from these issues, some DBS-specific analytical aspects should be addressed for every DBS 
method, especially when partial punches are analyzed. These parameters are the impact of the 
volume of blood spotted onto the filter paper, the punch localization and, undoubtedly the most 
discussed issue in DBS analysis, the influence of hematocrit. The latter problem, along with strategies 
to cope with it, has been reviewed recently by De Kesel et al [35]. 
In the last few years, several groups evaluated the utility of DBS for CYP450 phenotyping. By 
validating five individual LC-MS/MS methods for the determination of caffeine, flurbiprofen, 
midazolam, omeprazole and rosiglitazone, being substrates of CYP1A2, CYP2C9, CYP3A4, CYP2C19 
and CYP2C8, respectively, in 3-mm DBS punches, Lad et al. illustrated the idea of using DBS sampling 
for this purpose. However, specific metabolites of these probe drugs, enabling assessment of 
metabolic ratios, were not included and the developed methods were not applied in a phenotyping 
study [36].  
Since then, DBS-based phenotyping of single CYP450 isoforms has been investigated in several 
studies, summarized in Table 1. In a CYP3A4 phenotyping study, de Boer et al. determined 
midazolam concentrations in plasma, whole blood and volumetrically applied venous and capillary 
DBS of 12 healthy volunteers at different time points following administration of a single 7.5 mg 
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midazolam test dose. This approach allowed to construct pharmacokinetic (PK) profiles for the 
different matrices, from which AUC values were derived as CYP3A4 phenotyping metric [37]. 
Interestingly, while mean midazolam AUC values for venous and capillary DBS punches were 
comparable, mean AUC obtained from whole blood analysis was considerably lower. Although, based 
on high regression coefficients for venous DBS, whole blood and plasma, the authors concluded that 
the results for the evaluated sampling techniques were strongly correlated, we believe that this ‘DBS-
effect’ needs further examination before accepting the presented approach for CYP3A4 phenotyping. 
Furthermore, strongly deviating results for capillary DBS in some cases negatively impacted the 
correlation with the other matrices.  
More clear findings in favor of DBS sampling were described for other CYP450 enzymes. Déglon et al. 
developed an automated system for on-line desorption of DBS combined with LC-MS/MS analysis. 
This platform was used for the determination of the CYP2C9 probe substrate flurbiprofen and its 
metabolite 4-hydroxyflurbiprofen in whole, volumetrically applied 5 µL DBS [29]. The results of a PK 
study, involving administration of 50 mg flurbiprofen to 10 healthy volunteers, were described in a 
separate report by Daali et al. [38]. Concentration ratios of 4-hydroxyflurbiprofen to flurbiprofen, 
being measures of CYP2C9 activity, in capillary DBS collected at multiple time points post-
administration were in good agreement with corresponding ratios in plasma and urine and with 
flurbiprofen clearances, as evidenced by Spearman rank correlation coefficients. In addition, it was 
demonstrated that metabolic ratios in DBS and plasma changed in a similar way following CYP2C9 
induction and inhibition. Murphy et al. measured cotinine and trans 3’-OH-cotinine levels in plasma 
and non-volumetrically applied capillary DBS of smokers and non-smokers exposed to second hand 
smoke. As CYP2A6 mediates cotinine conversion to trans 3’-OH-cotinine, the resulting 
metabolite/precursor ratio is often used as CYP2A6 phenotyping metric. Ratios in DBS punches and 
corresponding plasma samples of 81 subjects were highly correlated, with a Spearman rank 
correlation coefficient of 0.94 (p < 0.001) [39]. We investigated whether DBS were suited for CYP1A2 
phenotyping using the established probe drug caffeine and its major metabolite paraxanthine [40]. 
Six hours after the intake of a 150 mg oral caffeine dose, paraxanthine/caffeine ratios were 
determined in plasma, whole blood and 3-mm punches of venous and non-volumetrically applied 
capillary DBS of 73 healthy volunteers. While capillary DBS concentrations were significantly lower 
than venous whole blood and plasma concentrations and DBS concentrations were influenced by 
hematocrit and blood volume spotted, both compounds were similarly affected. As a consequence, 
Bland-Altman and Passing-Bablok plots showed that paraxanthine/caffeine ratios, i.e. the CYP1A2 
phenotyping metric, were highly comparable in all matrices [41].  
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In addition to these single enzyme phenotyping studies, DBS have also been used to measure the 
activity of multiple CYP450 enzymes simultaneously by the administration of a cocktail of probe 
drugs. Donzelli et al. applied a new phenotyping cocktail, called the Basel cocktail, consisting of low 
doses of losartan (12.5 mg, for CYP2C9), omeprazole (10 mg, for CYP2C19), midazolam (2 mg, for 
CYP3A4), caffeine (100 mg, for CYP1A2), metoprolol (12.5 mg, for CYP2D6) and efavirenz (50 mg, for 
CYP2B6). This cocktail was administered to 16 healthy volunteers followed by non-volumetric 
collection of capillary DBS at different time points along with saliva samples and whole blood for 
plasma preparation. As a result of the low drug doses and the moderate sensitivity of the applied LC-
MS/MS method, only the pairs caffeine -  paraxanthine and omeprazole - 5-OH-omeprazole could be 
quantified in 3-mm DBS punches. As a measure of CYP1A2 activity, paraxanthine/caffeine ratios at 8 
h in DBS correlated with corresponding AUC ratios in plasma. Similar findings were obtained for 
omeprazole/5-OH-omeprazole ratios at 2 h in DBS, being the CYP2C19 phenotyping metric [42]. 
Bosilkovska et al. conducted a phenotyping study in which another combination of probe drugs, the 
Geneva cocktail, containing bupropion (25 mg, for CYP2B6), flurbiprofen (25 mg, for CYP2C9), 
omeprazole (5 mg, for CYP2C19), dextromethorphan (10 mg, for CYP2D6) and midazolam (1 mg, for 
CYP3A4), was administered to 10 healthy volunteers together with a cup of coffee (100 mg caffeine, 
for CYP1A2) or coke (25 mg caffeine). Also here, capillary and venous blood were collected at several 
time points after intake of the drug cocktail. DBS were prepared by spotting 10 µL of capillary blood 
on DBS cards and whole spots were analyzed. In contrast to Donzelli et al., the higher volume, 
combined with the use of more sensitive equipment, allowed quantification of all probe drugs and 
corresponding metabolites in DBS. Single point metabolite/parent drug ratios at 2 h for CYP1A2 and 
CYP3A4 and at 3 h for CYP2B6, CYP2C9 and CYP2D6, and the AUC2,3,6 metabolite/parent drug ratio for 
CYP2C19 showed acceptable Spearman rank correlation coefficients with AUClast ratios in plasma, 
both when the cocktail was administered alone or in combination with CYP450 inhibitor and inducer 
drugs [43,44].  
For almost all CYP450 enzymes evaluated in the cited studies, a good agreement between 
phenotyping metrics measured in DBS and conventional, mostly plasma-based, metrics was found. 
Therefore, DBS sampling seems to represent a minimally-invasive and patient-friendly alternative for 
traditional venous blood sampling to obtain high-quality phenotyping data. Given the ease of the 
sampling technique and the convenient transport, DBS are highly suitable to be implemented in 
large-scale phenotyping studies or even in home-sampling scenarios. To further accept DBS-based 
CYP450 phenotyping, other CYP450 isoforms should be investigated and the results of the above-
mentioned studies need to be confirmed in other, sufficiently large study populations. Future studies 
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may also consider to evaluate the impact of known issues, mainly hematocrit and blood volume, on 
DBS-based phenotyping metrics.  
3 Hair 
Hair analysis has become an established discipline in bioanalysis in the last decades with numerous 
published methods, mainly dealing with qualitative or quantitative determination of drugs of abuse, 
alcohol biomarkers or environmental contaminants. Collection and analysis of hair has been 
implemented in various fields, including forensic toxicology, investigation of drug-facilitated crimes, 
workplace drug testing, doping control in sports, detection of perinatal drug exposure and 
abstinence monitoring in driving license regranting programs or child custody cases [45,46]. The most 
important feature of hair analysis is probably the possibility to retrospectively assess drug use. Drugs 
that are incorporated into hair are no longer subject to biotransformation. As a consequence, many 
drugs proved to be stable in hair for prolonged periods of time, yielding a window of detection of 
several months or years, depending on hair length. Determination of drugs in specific hair segments 
even enables retrospective assessment of drug use that can be assigned to a defined time period in 
the past, taking into account an average hair growth rate of 1.06 cm/month [47]. Furthermore, being 
a non-invasive sampling technique, collection of hair samples can be performed by non-specialized 
personnel, although some expertise is required to avoid variation in the amount of hair left on the 
scalp [47]. Hair strands are typically collected from the posterior vertex region of the head, as hair 
growth rate shows less variability there [45,46]. Although hair analysis provides distinct benefits 
compared to traditional bioanalytical matrices, it also holds important limitations, especially 
concerning the interpretation of hair results. One of the main issues in hair analysis is the potential 
contribution of external contamination or passive drug exposure to measured hair concentrations. 
Therefore, hair samples are usually decontaminated prior to further processing, although a general 
consensus on standard wash procedures is currently lacking [48]. Several strategies have been 
proposed to distinguish active ingestion of a substance from external contamination, such as 
determining specific metabolites in hair and calculating metabolite/precursor concentration ratios, 
which can be compared with established cut-off values [49,50]. In addition, while analysis of hair 
segments has been widely applied to detect changes in drug consumption over time or to allocate 
drug intake to a certain period, interpretation of segmental hair analysis may be challenged due to 
external contamination [51]. On the other hand, analytes may also be removed from the hair as a 
result of damage caused by cosmetic hair treatment, such as bleaching or dyeing, leading to 
underestimation of hair concentrations [52]. Another factor impeding the interpretation of hair 
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results is the fact that, for many compounds, hair concentrations do not correlate with plasma or 
serum levels and, consequently, with drug dose.  
Apart from the above-mentioned, well-established applications, hair analysis has also been proposed 
for the assessment of drug metabolism. In 1996, Mizuno et al. determined caffeine in hair strands of 
6 healthy individuals and 6 patients with liver cirrhosis. Significantly higher caffeine concentrations 
were found in hair samples of liver cirrhosis patients. In a separate group of volunteers, the authors 
showed that elimination of a defined caffeine dose, based on saliva concentrations, was slower in 
patients with liver disease compared to healthy individuals. This led the authors to suggest that 
caffeine concentrations in hair could be used as an indicator of liver metabolic capacity. It should be 
noted, however, that no data were available on caffeine intake of the individuals whose hair samples 
were analyzed and no metabolites of caffeine were measured in hair to make a more conclusive 
statement on metabolic capacity [53]. To date, 2 studies evaluated the usefulness of hair analysis for 
the assessment of CYP450-mediated metabolism by correlating metabolic ratios in hair with enzyme 
genotypes or reference phenotyping metrics (Table 1). Thieme et al. analyzed hair samples of 23 
children for which illegal, prolonged administration of the antidepressant amitriptyline was 
suspected. The N-demethylation of amitriptyline to nortriptyline is mediated by CYP2C19. While 
nortriptyline/amitriptyline ratios did not change significantly along individual hairs, large 
interindividual variations in these ratios were observed. The authors found a clear correlation 
between nortriptyline/amitriptyline ratios in hair and the number of functional alleles of CYP2C19. In 
particular, CYP2C19 poor metabolizers, carrying 2 dysfunctional alleles, had significantly lower hair 
ratios compared to intermediate or extensive metabolizers. Apart from CYP2C19, also CYP2D6 is 
involved in amitriptyline and nortriptyline metabolism by mediating the hydroxylation of both 
compounds. Despite wide interindividual variability, no correlation between hydroxylation of 
amitriptyline and nortriptyline and CYP2D6 polymorphisms was found. This was probably due to the 
fact that only intermediate and extensive, and no poor or ultrarapid CYP2D6 metabolizers were 
present in the study population [54]. In a recent study of our group, we evaluated the potential of 
hair analysis for CYP1A2 phenotyping. Paraxanthine/caffeine concentration ratios were determined 
in proximal 3-cm hair segments of 60 healthy volunteers. Hair ratios of all subjects were compared 
with a reference CYP1A2 phenotyping metric, being paraxanthine/caffeine ratios in plasma 6 hours 
after intake of a caffeine test dose (150 mg).  While ratios in both matrices showed a similar range 
and a statistically significant correlation, large differences between hair and plasma ratios were seen 
in individual cases. These deviations could not be attributed to factors potentially affecting the 
incorporation or retention of small molecules in hair, such as hair pigmentation and cosmetic hair 
coloring, or affecting CYP1A2 activity, such as oral contraceptives, smoking, gender, age and caffeine 
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consumption. On the basis of these results, we concluded that hair analysis is not (yet) suitable for 
CYP1A2 phenotyping, as interpreting paraxanthine/caffeine hair ratios on an individual basis was 
difficult [55].  
Hair analysis has also been used as a tool to retrospectively document changes in CYP450-mediated 
metabolism over time by determining metabolic ratios in consecutive hair segments. In particular, 
this approach has been applied in several studies to detect pregnancy-induced altered metabolism. 
Klein et al. collected hair samples of 28 smoking women during the postpartum period and divided 
the obtained samples into segments corresponding to the trimesters of pregnancy. All volunteers 
reported a consistent smoking behavior throughout pregnancy and concentrations of nicotine and its 
major metabolite cotinine were determined in all segments. Nicotine/cotinine ratios in the third 
trimester were significantly decreased compared to those in the first trimester. According to the 
authors, these findings illustrated that nicotine metabolism to cotinine, mainly catalyzed by CYP2A6, 
increases as pregnancy advances [56], which was in agreement with previous findings [57]. In a more 
recent study by the same group, similar results for nicotine/cotinine ratios in hair of 74 smoking 
women were obtained [58]. O’Brien et al. applied an analogous approach to examine changes in 
antidepressant metabolism during pregnancy. Citalopram/norcitalopram ratios in hair segments 
corresponding to the first and third trimester of pregnancy were significantly lower than ratios in the 
postpartum period [59]. Although only 4 women were included, these findings could confirm the 
elevated metabolism of citalopram [60] and increased CYP2D6 activity during pregnancy [61-63]. 
Finally, Himes et al. analyzed hair samples from 29 opioid-dependent pregnant women enrolled in 
methadone-assisted therapy. Methadone and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
(EDDP), the major metabolite of methadone, were measured in proximal 3-cm hair segments 
collected throughout pregnancy. In addition, cumulative methadone doses taken during the time 
interval corresponding to the analyzed hair segments were calculated. A positive linear trend 
between this cumulative dose and EDDP/methadone ratios in hair was observed [64]. This could 
illustrate auto-induction of methadone metabolism, mainly mediated by CYP3A4 [65], or, again, 
elevated CYP450 activity during pregnancy [61-63]. These studies suggest that applying segmental 
hair analysis to retrospectively assess drug metabolism may hold promise as an alternative 
phenotyping approach. Here, hair analysis, due to its distinct characteristics, provides a tool to gain 
information on a subject’s metabolic status that could not have been obtained by analyzing 
traditional matrices (blood or urine),  given their much shorter time window of detection. On the 
other hand, although altered drug metabolism during pregnancy is a generally recognized concept, it 
should be noted that in none of the above mentioned studies the metabolic ratios measured in hair 
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were compared with reference phenotyping indices determined in other matrices to support their 
validity in reflecting changed metabolism.  
In general, in contrast to traditional phenotyping procedures, the probe drugs used to estimate 
enzyme function in the cited hair methods were not specifically administered for this purpose. To 
determine metabolic ratios in hair, these methods relied on intake or administration of therapeutic 
drugs or intake of enzyme substrates via cigarette smoke or nutrition, leading to variation in the 
duration of exposure and the amount of ingested or inhaled compounds between individuals. 
Another factor that needs to be taken into account when metabolic ratios in hair are evaluated, is 
the possibility that metabolites and precursors may be incorporated into hair to a different extent. It 
is generally accepted that compounds are incorporated into hair from the bloodstream, sweat or 
sebum or through external contamination [66]. Several compound-dependent factors affect these 
processes, such as their physicochemical properties and affinity for binding to melanin in hair. In 
addition, analytical hair decontamination procedures or external influences, such as regular hair 
washing, influence of UV-light and cosmetic treatment of hair, may potentially cause differential loss 
of metabolites and precursors from the hair [45]. Therefore, as many variables may impact analyte 
concentrations in hair, the usefulness of hair metabolic ratios needs to be evaluated on a case by 
case basis and should be supported by controls in other matrices or data on enzyme genotypes. 
Futhermore, as hair results are likely to provide an average image of the enzyme phenotype, short-
term changes in enzyme activity will not be detected by hair analysis, in contrast to DBS- or oral fluid-
based phenotyping procedures. 
4 Oral fluid 
Collection of oral fluid as an alternative to plasma has been applied in diverse areas. For example, as 
concentrations in oral fluid reflect the free, non-protein bound, pharmacologically active fraction of a 
drug in plasma, oral fluid sampling has gained attention as a tool for therapeutic monitoring of 
selected drugs [67]. Currently, the best established applications of oral fluid are probably roadside 
and workplace drug testing [68,69]. Rapid, simple and non-invasive sample collection are important 
advantages of oral fluid sampling. As a consequence, samples may be collected by non-experienced 
individuals and repeated sampling can be done more easily. Compared to blood sampling, the risk of 
infection is lower. Oral fluid is usually obtained by drooling or spitting in a dedicated collection device 
or by absorbent swabs. To hasten sample collection and increase the sampled volume, oral fluid flow 
can be stimulated, e.g. by citric acid or chewing paraffin wax. However, stimulation may affect drug 
concentrations due to the dilution effect and an altered pH of the oral fluid. Other challenges 
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associated with oral fluid analysis are adsorption of analytes to collection devices, interferences from 
food or drinks and contamination with orally ingested or inhaled drugs left in the mouth [70-72].    
Oral fluid sampling has been evaluated in phenotyping studies involving several CYP450 enzymes 
(Table 1). The CYP1A2 substrate caffeine is by far the most investigated and applied probe drug in 
oral fluid-based phenotyping procedures. Starting from the 1980’s, collection of oral fluid has been 
used for the measurement of caffeine clearance as an indicator of liver function, with several studies 
showing an excellent agreement between PK parameters derived from oral fluid and serum or 
plasma samples [73-79]. Fuhr et al. evaluated the usefulness of caffeine as CYP1A2 phenotyping 
probe drug by performing a meta-analysis of 4 studies in which caffeine and paraxanthine had been 
measured in plasma, urine and oral fluid samples of 78 subjects. It was concluded that caffeine 
clearance from oral fluid and 3-7 h post-dose paraxanthine/caffeine ratios in both oral fluid and 
plasma were highly correlated with systemic caffeine plasma clearance, providing a better estimate 
of CYP1A2 activity than urinary ratios [80]. Furthermore, in a study involving 25 patients undergoing 
hepatectomy, significant correlations were found between in vivo parameters of CYP1A2 activity, 
being caffeine clearance and paraxanthine/caffeine ratios (3 and 6 h post-dose) in oral fluid or 
plasma, and in vitro parameters, being caffeine 3-demethylation and relative CYP1A2 content in liver 
microsomes [13]. Since then, the validity of oral fluid for CYP1A2 phenotyping was corroborated by 
several other studies [81-87] and, consequently, this approach has been widely applied to assess 
CYP1A2 activity in various settings [61,85,86,88-98].  
As urinary dextromethorphan metabolic ratios for CYP2D6 phenotyping are affected by considerable 
intraindividual variability, Hou et al. evaluated the use of oral fluid for this purpose. 
Dextromethorphan/dextrorphan ratios in oral fluid samples of 61 healthy volunteers, measured 3 h 
following dextromethorphan administration, showed a significant correlation with 0-8 h urinary 
ratios and enabled to differentiate all CYP2D6 poor metabolizers from intermediate and extensive 
metabolizers identified by urinary metabolic ratios. The latter 2 groups, however, could not be 
separated on the basis of oral fluid results [99]. The applicability of this method and its potential to 
provide an alternative for urine-based CYP2D6 phenotyping was demonstrated in 100 anuric patients 
with renal failure [100]. However, in a study with repetitive dextromethorphan administration, Hu et 
al. observed poor repeatability of 3, 4, and 5 h oral fluid dextromethorphan/dextrorphan ratios. The 
authors proposed to use 6 h ratios instead, as these showed good repeatability and correlated 
significantly with urinary phenotyping metrics [101]. In addition, Lutz et al. were able to differentiate 
CYP2D6 poor metabolizers in a population of 170 volunteers using 2 h oral fluid 
dextromethorphan/dextrorphan ratios. Comparison with other phenotyping metrics or genotypic 
data was not included in this study [102].  
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While the latter procedures were based on the CYP2D6-mediated O-demethylation of 
dextromethorphan to dextrorphan, Kuo et al. proposed to use another metabolic route of 
dextromethorphan, N-demethylation to 3-methoxymorphinan, for CYP3A phenotyping. However, 
dextromethorphan/3-methoxymorphinan ratios in oral fluid of 3 volunteers showed a poor 
correlation with corresponding urinary ratios [103]. Based on good correlations between midazolam 
concentrations in plasma and oral fluid, determined in 8 subjects at multiple time points, Link et al. 
suggested that midazolam may provide a suitable probe drug for oral fluid-based CYP3A 
phenotyping. However, it should be noted that, due to the high plasma protein binding of 
midazolam, the common CYP3A phenotyping metrics AUC and clearance were considerably lower 
and higher, respectively, in saliva compared to plasma [104]. As mentioned in the section on DBS, 
Donzelli et al. tested a cocktail of probe drugs to simultaneously measure the activity of multiple 
CYP450 enzymes. Along with DBS, oral fluid samples were collected from 16 volunteers. Similar to 
DBS results, oral fluid concentrations of most probe drugs were below the LLOQ. 
Paraxanthine/caffeine ratios at 8 h in oral fluid, being the CYP1A2 phenotyping metric, showed a 
significant correlation with corresponding AUC ratios in plasma. As a potential measure of CYP2C19 
activity, omeprazole/5-OH-omeprazole ratios at 2 h in oral fluid correlated poorly with corresponding 
AUC ratios in plasma [42]. 
The role of nicotine metabolites and corresponding metabolic ratios in various matrices, including 
oral fluid, as biomarkers of exposure to tobacco smoke, smoking cessation or to guide treatment of 
nicotine dependence has been thoroughly explored, as indicated in several studies and recent review 
papers [105-110]. Here, we will discuss studies that specifically evaluated the usefulness of nicotine 
metabolic ratios in oral fluid for CYP2A6 phenotyping. A first proof was provided by Dempsey et al., 
who administered deuterium labeled nicotine and cotinine to 62 healthy volunteers. Resulting trans 
3’-OH-cotinine/cotinine ratios in oral fluid 6 h post-intake were highly correlated with several indices 
of CYP2A6 activity, including 6 h ratios in plasma and oral clearance of both nicotine and cotinine 
[111]. CYP2A6 phenotyping based on trans 3’-OH-cotinine/cotinine ratios originating from nicotine in 
tobacco smoke was examined by St. Helen et al. Regression analysis revealed high correlations 
between ratios in oral fluid and both whole blood and plasma of smokers and nonsmokers exposed 
to tobacco smoke. Bland-Altman analysis confirmed the agreement between oral fluid and whole 
blood, while this was not the case for the oral fluid-plasma comparison. Potential causes of the latter 
discrepancy were not further addressed. Overall, the authors concluded that all matrices provided 
similar measures of nicotine metabolism [112]. In another study, Lea et al. addressed the 
intraindividual variation of oral fluid trans 3’-OH-cotinine/cotinine ratios in 6 regular daily smokers 
and observed that ratios were not affected by the time of sampling during the day [113].  
17 
 
In conclusion, oral fluid may provide a reliable alternative for plasma-based CYP450 phenotyping. 
Given the easy, rapid and non-invasive sample collection, this technique seems particularly suited for 
large epidemiological phenotyping studies. From the many available studies it can be stated that oral 
fluid has been established as a valid alternative sampling method for CYP1A2 phenotyping, with 
caffeine clearance or the paraxanthine/caffeine ratio as metrics. Although promising data were 
obtained for other CYP isoforms, such as CYP2D6 and CYP2A6, further studies are needed to confirm 
the results with these enzymes. 
5 Exhaled breath 
In the past 40 years, breath analysis has been extensively explored as a diagnostic tool to examine 
liver function. Typically, these breath tests are based on oral or intravenous administration of an 
isotopically labeled test compound. While radioactive 14C-labeled compounds were initially used, 
probe drugs carrying a functional group in which a stable 13C-isotope replaces a 12C-atom have now 
become standard practice, thereby providing a safer alternative. Upon administration, the probe 
drug is subject to metabolism and the labeled functional group is enzymatically cleaved. Following 
additional oxidation reactions, 13CO2 is  eventually formed. The latter is mixed with the body 
bicarbonate pool and exhaled in the breath. The 13CO2/
12CO2 ratio in breath samples, measured by 
isotope ratio mass spectrometry or isotope-selective nondispersive infrared spectrometry, has been 
used as an indicator of liver function. Usually, the 13C-enrichment of breath following administration 
of the probe drug is compared to the baseline enrichment before ingestion, as several factors (e.g. 
diet) may cause variations in the natural occurrence of 13CO2. Therefore, the final results are 
expressed as delta-over-baseline (DOB) values [114-116]. 
Apart from their use to investigate liver function, 13C breath tests have been applied to quantitatively 
assess the activity of metabolic enzymes. For many probe drugs, the initial metabolic reaction, often 
a dealkylation step, is catalyzed by CYP450 enzymes and, therefore, the amount of 13CO2 in breath 
should reflect enzyme activity. For a full overview of published breath tests, available probe drugs 
and their clinical utility, we refer to several recent reviews on this topic [117-121]. Here, we highlight 
a number of selected studies in which the potential of breath tests for CYP450 phenotyping has been 
evaluated by comparison with other indices of enzyme activity (Table 1). The N-demethylation of 
aminopyrine, the first probe drug used in breath tests, is mediated by several CYP450 enzymes, with 
CYP2C19 being the most important isoform [122]. Kodaira et al. found a significant correlation 
between AUC0-3h of DOB 
13CO2/
12CO2 ratios and both plasma [
13C]-aminopyrine AUC0-3h and clearance 
[123]. [13C]-pantoprazole has been proposed as an alternative CYP2C19 phenotyping probe, as 
several studies found significantly lower DOB values in CYP2C19 poor metabolizers compared to 
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intermediate or extensive metabolizers [124-129]. In addition, plasma [13C]-pantoprazole AUC 
correlated significantly with the AUC of DOB 13CO2/
12CO2 ratios [124,127,129].  
Leeder et al. developed a new breath test for CYP2D6 phenotyping using [13C]-dextromethorphan as 
probe drug. Single 40 min DOB 13CO2/
12CO2 ratios proved equally effective as urinary [
13C]-
dextromethorphan/dextrorphan ratios in distinguishing between CYP2D6 poor and extensive 
metabolizers [130]. The utility of this approach was evaluated by Opdam et al. in a study involving 
breast cancer patients taking tamoxifen, a prodrug that is converted to endoxifen by CYP2D6. The 
correlation between CYP2D6 phenotype, determined by the [13C]-dextromethorphan breath test, and 
serum endoxifen levels was comparable with the correlation between the latter and sequence-based 
CYP2D6 activity prediction [131]. For the CYP1A2 substrate [13C]-caffeine, Park et al. observed a 
significant  correlation between 1 h single DOB 13CO2/
12CO2 ratios and plasma [
13C]-caffeine clearance 
[132]. These results were in agreement with previous studies, in which excellent correlations 
between caffeine breath test results and caffeine clearance were found [133-136].  
One of the most widely applied phenotyping procedures is the erythromycin breath test, although 
several studies revealed conflicting results concerning its ability to reflect CYP3A4 phenotype, 
especially in relation to the established CYP3A4 phenotyping probe drug midazolam. While Lown et 
al. found a significant correlation between erythromycin breath test results, expressed as % 14C 
exhaled in 1 h, and body weight-adjusted clearance of midazolam [137], these results could not be 
confirmed in other studies applying identical PK parameters [138,139]. Franke et al. used 1/Tmax as an 
alternative erythromycin breath test parameter, but found no correlation with midazolam clearance 
either [140]. The fact that, in addition to CYP3A4, P-glycoprotein is involved in erythromycin 
metabolism, whereas this is not the case for midazolam, may explain the discordant results for both 
probe drugs [141].  
In general, breath tests based on the administration of isotopically labeled probe drugs seem to 
provide an interesting, non-invasive alternative to assess the activity of several CYP450 enzymes. 
Breath samples are easily collected and do not require extensive sample work-up prior to analysis. 
However, widespread routine use of breath tests for phenotyping purposes has been limited to date, 
due to the high cost of isotopically labeled compounds and the highly specialized equipment required 
for analysis of breath samples.  
6 Miscellaneous matrices 
In addition to the above-mentioned matrices, many endogenous compounds and xenobiotics are, to 
a limited extent, secreted into sweat as well. Several applications of sweat testing have been 
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described, including measurement of chloride ions as a biomarker of cystic fibrosis [142] and 
detection of drugs of abuse in forensic toxicology, roadside and workplace drug testing [143-145]. 
Sweat for drug testing is commonly collected using transdermal absorptive sweat patches attached 
to the skin, representing a non-invasive sampling technique. In most cases, analytes can be removed 
from these patches using relatively simple extractions protocols, resulting in clean extracts that are 
subsequently analyzed by GC- or LC-MS. Sweat patches can be worn for several days, enabling 
continuous drug testing over an extended period of time compared to urine, saliva or blood. 
Limitations of this sampling strategy are the potential influence of external contamination of the 
devices or the skin and the unknown collected volume, as sweat production may vary in function of 
ambient temperature or physical activity [145]. Delahunty et al. suggested that sweat could 
potentially be used as an alternative for urine or plasma to estimate CYP1A2 activity. Following 
administration of caffeine, the latter compound and its metabolites were determined in transdermal 
absorptive sweat patches worn for several days by healthy volunteers. Caffeine, paraxanthine and 
theobromine were readily detected in the patches, allowing to calculate metabolite/parent drug 
ratios [146]. However, comparison of these ratios with corresponding ratios in plasma or urine, to 
illustrate their actual usefulness for CYP1A2 activity assessment, was not included in the study. To 
the best of our knowledge, no other studies on the use of sweat for CYP450 phenotyping are 
available to date. Kuwaya et al. developed a method that allowed to determine caffeine and 
parxanthine in fingerprints at several time points following consumption of a cup of coffee. Although 
this concept may hold promise for CYP1A2 phenotyping, paraxanthine/caffeine ratios were not 
calculated [147]. 
Another example of using an alternative matrix for measuring CYP450 activity was described by 
Grosso et al. In a study to investigate the association between intrauterine growth restriction (IUGR) 
and fetal caffeine exposure, caffeine and its primary metabolites were quantified in umbilical cord 
serum samples of 1606 women. As higher paraxanthine/caffeine ratios were positively correlated 
with an increased risk of IUGR, it was suggested that CYP1A2 activity may have an effect on fetal 
growth [148].  
7 Conclusion 
A substantial number of studies has evaluated the usefulness of DBS, hair, oral fluid or exhaled 
breath as alternative sampling strategies for CYP450 phenotyping. A large body of evidence supports 
the validity of oral fluid for CYP1A2 phenotyping, using caffeine as a probe drug. While this method 
has already been implemented in several phenotyping studies, promising results were also obtained 
for other oral fluid-based phenotyping approaches, especially for nicotine metabolic ratios as a 
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measure of CYP2A6 activity and the CYP2D6 probe drug dextromethorphan. CYP3A phenotyping in 
oral fluid following midazolam or dextromethorphan administration needs further investigation. 
Concerning the utility of exhaled breath as an alternative matrix for CYP450 phenotyping, the 
available data are, in some respect, comparable to those of oral fluid. While [13C]-caffeine and [13C]-
dextromethorphan breath tests proved to be reliable procedures for CYP1A2 and CYP2D6 
phenotyping, respectively, conflicting results were obtained for the assessment of CYP3A4 activity 
using the widely applied probe drug [14C]-erythromycin. [13C]-pantoprazole-based breath tests, on 
the other hand, showed promise to assess CYP2C19 metabolizer status. Recently, several groups 
proposed DBS sampling as an alternative strategy for CYP450 phenotyping. Procedures for several 
clinically relevant CYP450 isoforms, including CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19 and 
CYP2D6, revealed good agreement between phenotyping metrics determined in DBS and in plasma. 
Also here, inconclusive data were obtained for CYP3A4 phenotyping using midazolam as probe drug. 
Although hair sampling may provide an interesting tool in case a standard phenotyping procedure is 
not feasible (e.g. post-mortem), the actual value of hair analysis in this field remains to be 
established, given the limited number of studies available to date. 
Based on the studies discussed in this review, it can be concluded that reliable phenotyping 
procedures for selected CYP450 enzymes are currently available for either oral fluid, breath and DBS. 
Important to note is that it should be decided on a case-by-case basis what phenotyping metric is to 
be used. While in many of the described alternative procedures metabolic ratios at one given time 
point have been used as phenotyping metric, other metrics (e.g. AUC, clearance, etc.) may be more 
appropriate in other scenarios. Also here -especially when repeated sampling is to be performed- 
these alternative matrices offer the benefit that they can be collected in a non- or minimally invasive 
way, causing minimal discomfort for the patient. Table 2 summarizes selected advantages and 
limitations of the alternative sampling strategies. To date, phenotyping of drug metabolizing 
enzymes has been mainly applied in research settings, for example in drug-drug interaction studies 
or to assess the impact of various factors, such as gender, age, diet or cigarette smoke, on enzyme 
activities. The availability of simple, convenient and patient-friendly protocols may hasten the 
acceptance and routine application of CYP450 phenotyping in clinical practice as well. There, 
phenotyping could play a role in predicting optimal drug dose prior to the start of the therapy or to 
guide therapy in case of unexpected changes in plasma levels of (or response to) a given drug. 
Examples of therapeutic drugs for which phenotyping using alternative strategies may be applied are 
the CYP2D6 substrates imipramine, nortriptyline (tricyclic antidepressants), haloperidol, risperidone 
(antipsychotics), codeine and tramadol (opioid analgesics), the CYP2C19 substrates omeprazole, 
lansoprazole (proton-pump inhibitors) and clopidogrel (platelet aggregation inhibitor), the CYP1A2 
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substrates clozapine and olanzapine (antipsychotics) and the CYP2C9 substrate warfarin 
(anticoagulant) [3,6,8]. For several of these, it remains to be fully established if and to what extent 
phenotyping (and resulting dose adaptation) indeed results in a better clinical outcome.  
Furthermore, in contrast to venous blood sampling, collecting DBS, oral fluid or breath does not 
require a phlebotomist and can be performed by instructed patients themselves. In this light, a 
phenotyping scenario involving home-sampling may be envisaged, in which samples are transferred 
to the laboratory by mail, provided that the analytes of interest are stable under the transport 
conditions. In our opinion, DBS sampling may be the preferred approach for this purpose, given the 
ease of transport and storage of DBS cards compared to oral fluid and, especially, breath samples 
collected in dedicated bags. The required analytical instrumentation is another factor that may 
determine which alternative sampling strategy is best suited to allow a more widespread use of 
phenotyping. While DBS and oral fluid can be analyzed using techniques that have become standard 
in the modern clinical laboratory, such as LC-MS/MS, measurement of 13CO2/
12CO2 ratios in breath 
requires highly specialized equipment not commonly available in such laboratories. In recent years, 
microdosing of probe drugs has been applied in phenotyping studies to reduce the risk of adverse 
drug reactions or interferences with other drugs. Since doses are at least 100-fold lower than regular 
doses, highly sensitive, accurate and precise analytical procedures are required [149]. While this 
already represents a challenge for microdosing approaches using plasma, it may especially pose a 
problem when alternative sampling strategies are to be applied. DBS methods, for example, typically 
analyze only a few µl of dried blood. For oral fluid, other issues, such as drug adsorption to sampling 
devices, may play a role. Alternative sampling strategies have -to the best of our knowledge- not yet 
been applied in microdosing studies. This may, however, be an interesting future application taking 
into account the increasing sensitivity of the latest generations of LC-MS/MS instruments. Finally, for 
alternative sampling techniques to become fully accepted as valid phenotyping strategies, the results 
obtained to date need to be confirmed in future studies, including trials in subjects with deviating 
enzyme activity and large population studies, allowing to define reference ranges of phenotyping 
metrics in the various matrices.   
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Table 1. CYP450 phenotyping procedures using dried blood spots (DBS), hair, oral fluid and exhaled 
breath. 
DBS: dried blood spots, CYP: cytochrome P, AUC: area under the curve, LLOQ: lower limit of quantification, PM: poor 
metabolizer, IM: intermediate metabolizer, EM: extensive metabolizer 
 
Table 1 continued. CYP450 phenotyping procedures using dried blood spots (DBS), hair, oral fluid and 
exhaled breath. 
Matrix CYP450 isoform Probe drugs Phenotyping metric Comments References 
DBS CYP3A4 Midazolam Midazolam AUC0-12h Unexplained difference between DBS and 
whole blood AUC 
[37] 
 CYP2C9 Flurbiprofen OH-flurbiprofen/flurbiprofen 
ratio (multiple time points) 
Significant correlation with plasma and 
urine ratios and flurbiprofen clearance 
[29,38] 




Significant correlation with plasma ratios [39] 
 CYP1A2 Caffeine 6 h paraxanthine/caffeine ratio Significant correlation with whole blood 
and plasma ratios, examination of DBS-
specific parameters 
[40,41] 
 CYP2C19, CYP1A2,   
CYP3A4, CYP2C9, CYP2D6, 
CYP2B6 
Omeprazole, caffeine, 
midazolam, losartan  
metoprolol, efavirenz 
2h omeprazole/OH-omeprazole 
& 8 h paraxanthine/caffeine 
ratio (other probe drugs or 
metabolites < LLOQ) 
Significant correlation with plasma AUC 
ratios 
[42] 
 CYP3A4,  CYP1A2, CYP2B6,  
CYP2C9, CYP2D6, CYP2C19 
Midazolam, caffeine, 
bupropion, flurbiprofen,  
dextromethorphan, 
omeprazole 
2 h OH-midazolam/midazolam 
& paraxanthine/caffeine ratio, 3 
h OH-bupropion/bupropion,  
OH-flurbiprofen/flurbiprofen & 
dextrorphan/dextromethorpha
n ratio, AUC2,3,6h OH-
omeprazole/omeprazole ratio 
Significant correlation with plasma AUC 
ratios 
[43,44] 
Hair CYP2C19 Amitriptyline Nortriptyline/amitriptyline ratio 
in entire hair samples 
Significant differences between PM and 
IM/EM 
[54] 
 CYP1A2 Caffeine Paraxanthine/caffeine ratio in 
proximal 3-cm segments 
Overall significant correlation with 6 h 
paraxanthine/caffeine plasma ratios, but 
large deviations in individual cases 
[55] 
Matrix CYP450 isoform Probe drugs Phenotyping metric Comments References 
Oral fluid CYP1A2 Caffeine Caffeine clearance and 3-10 h 
paraxanthine/caffeine ratios 
Significant correlation with caffeine 
plasma/serum clearance, 
paraxanthine/caffeine plasma ratios and 
in vitro CYP1A2 activity 
[13,80,82-
87] 
 CYP2D6 Dextromethorphan 3 or 6 h  
dextromethorphan/dextrorpha
n ratio 
Significant correlation with urinary 
dextromethorphan/dextrorphan ratios 
and differentiation between PM and 
IM/EM 
[99,101] 
 CYP3A Dextromethorphan 8 and 12 h   Poor correlation with  urinary  [103] 
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CYP: cytochrome P, AUC: area under the curve, LLOQ: lower limit of quantification, PM: poor metabolizer, IM: intermediate 




Table 1 continued. CYP450 phenotyping procedures using dried blood spots (DBS), hair, oral fluid and 
exhaled breath. 
CYP: cytochrome P, AUC: area under the curve, DOB: delta-over-baseline, PM: poor metabolizer, IM: intermediate 
metabolizer, EM: extensive metabolizer,  






methoxymorphinan  ratio 
dextromethorphan/3-methoxymorphinan  
ratios 
  Midazolam Midazolam AUC and clearance Large differences with plasma AUC and 
clearance 
[104] 
 CYP2C19, CYP1A2,   
CYP3A4, CYP2C9, CYP2D6, 
CYP2B6 
Omeprazole, caffeine, 
midazolam, losartan  
metoprolol, efavirenz 
2h omeprazole/OH-omeprazole 
& 8 h paraxanthine/caffeine 
ratio (other probe drugs or 
metabolites < LLOQ) 
Correlation with plasma AUC ratios 
significant for CYP1A2, poor for CYP2C19 
[42] 
 CYP2A6 Nicotine-d2, cotinine-d4 6 h trans 3’-OH-cotinine-
d4/cotinine-d4 ratio 
Significant correlation with plasma ratios 
and oral clearance of nicotine and cotinine 
[111] 




High correlation with whole blood ratios, 
not consistently similar with plasma ratios 
[112] 
Matrix CYP450 isoform Probe drugs Phenotyping metric Comments References 
Exhaled breath CYP2C19 [
13






Significant correlation with plasma [
13
C]-








CO2 ratio (multiple 
time points & AUC) 
Significant differences between PM and 













Comparable with urinary [
13
C]-
dextromethorphan/dextrorphan ratios to 

























Table 2. Authors’ view on main advantages and limitations of dried blood spot (DBS), oral fluid and 
exhaled breath sampling. 
 DBS Oral fluid Exhaled breath 
Patient comfort  
(incl. ease of sampling, 
invasiveness) 
++ ++ +++ 
Sampling in absence of 
specialized 
+++ +++ +++ 
Transport & storage +++ ++ - 
Home-sampling potential +++ ++ + 
Analysis using standard 
analytical equipment 
+++ +++ - 
 
 
